Synthetic Lethal Interaction Between Oncogenic KRAS and Mitochondrial Glutamate Transporter SLC25A22 Unveils a Novel Therapeutic Target in KRAS-Mutant Colon Cancer

被引：0
|
作者：
Wong, Chi Chun
Qian, Yun
Zhao, Liuyang
Kang, Wei
To, Ka Fai
Sung, Joseph J. Y.
Yu, Jun
机构：
来源：
GASTROENTEROLOGY | 2015年 / 148卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
48
引用
收藏
页码：S14 / S15
页数：2
相关论文
共 13 条
  • [1] SLC25A22 DRIVES IMMUNE SUPPRESSION IN KRAS-MUTANT COLORECTAL CANCER
    Zhou, Qiming
    Peng, Yao
    Chen, Lam-Shing
    Chen, Huarong
    Kang, Wei
    Nie, Yuqiang
    Yu, Jun
    Wong, Chi Chun
    GUT, 2021, 70 : A53 - A55
  • [2] Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
    Zhou, Qiming
    Peng, Yao
    Ji, Fenfen
    Chen, Huarong
    Kang, Wei
    Chan, Lam-Shing
    Gou, Hongyan
    Lin, Yufeng
    Huang, Pingmei
    Chen, Danyu
    Wei, Qinyao
    Su, Hao
    Liang, Cong
    Zhang, Xiang
    Yu, Jun
    Wong, Chi Chun
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [3] Targeting of SLC25A22 boosts the immunotherapeutic response in KRAS-mutant colorectal cancer
    Qiming Zhou
    Yao Peng
    Fenfen Ji
    Huarong Chen
    Wei Kang
    Lam-Shing Chan
    Hongyan Gou
    Yufeng Lin
    Pingmei Huang
    Danyu Chen
    Qinyao Wei
    Hao Su
    Cong Liang
    Xiang Zhang
    Jun Yu
    Chi Chun Wong
    Nature Communications, 14
  • [4] SLC25A22 Is Essential for Supporting Aspartate Biosynthesis and Is a Specific Vulnerability in KRAS-Mutant Colorectal Cancer
    Wong, Chi Chun
    Li, Xiaona
    Qian, Yun
    Xu, Jiaying
    Kang, Wei
    To, Ka Fai
    Sung, Joseph
    Cai, Zongwei
    Yu, Jun
    GASTROENTEROLOGY, 2016, 150 (04) : S139 - S139
  • [5] SLC25A22 DRIVES ONCOMETABOLITE SUCCINATE TO PROMOTE WNT/ß-CATENIN SIGNALING AND CANCER STEMNESS IN KRAS-MUTANT COLORECTAL CANCER
    Wong, Chi Chun
    Xu, Jiaying
    Li, Weilin
    Qian, Yun
    Kang, Wei
    Wu, Jianlin
    Sung, Joseph J.
    Yu, Jun
    GASTROENTEROLOGY, 2019, 156 (06) : S188 - S188
  • [6] Ephrins/eph as novel synthetic lethal targets in Kras-mutant colorectal cancer
    Van Schaeybroeck, S.
    Allen, W. L.
    Dunne, P.
    Jithesh, P.
    Longley, D.
    Johnston, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] A dual gene combination therapy approach by KRAS-G12V gene editing and SLC25A22 gene silencing for KRAS-mutant colorectal cancer
    Jin, Jiaying
    Li, Yijia
    Deng, Feiyang
    Yang, Long
    Lin, Yuxing
    Yang, Canyu
    Dai, Wenbing
    Zhang, Hua
    He, Bing
    Zhang, Qiang
    Wang, Xueqing
    NANO TODAY, 2024, 56
  • [8] SLC25A22 DRIVES IMMUNE SUPPRESSION IN KRAS-MUTANT COLORECTAL CANCER VIA METABOLIC REGULATION OF CXCL1/CXCR2 AXIS
    Zhou, Qiming
    Peng, Yao
    Chan, Lam-Shing
    Chen, Huarong
    Kang, Wei
    Nie, Yuqiang
    Yu, Jun
    Wong, Chi Chun
    GASTROENTEROLOGY, 2021, 160 (06) : S621 - S621
  • [9] LC-MS-based metabolomics revealed SLC25A22 as an essential regulator of aspartate-derived amino acids and polyamines in KRAS-mutant colorectal cancer
    Li, Xiaona
    Chung, Arthur C. K.
    Li, Shangfu
    Wu, Lilan
    Xu, Jiaying
    Yu, Jun
    Wong, Chichun
    Cai, Zongwei
    ONCOTARGET, 2017, 8 (60) : 101333 - 101344
  • [10] Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS-mutant Cancer Models
    Corcoran, R.
    Cheng, K.
    Hata, A.
    Faber, A.
    Singh, A.
    Settleman, J.
    Benes, C.
    Mino-Kenudson, M.
    Wong, K.
    Engelman, J.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 46 - 46
12